

# Neoadjuvant Chemotherapy for Breast Cancer – QUESTIONS

Clinical Case Conference  
UCSD Radiation Oncology  
SA-CME

1. In the NSABP B-18 trial, which patient group was given tamoxifen?
  - A) Estrogen receptor positive
  - B) Neoadjuvant chemotherapy
  - C) Age  $\geq$  50
  - D) Lumpectomy
  - E) All patients
2. In both the B-18 and the B-27 trials, which of the following factors was significantly predictive of an improvement in overall survival?
  - A) Complete pathologic response to neoadjuvant chemotherapy
  - B) Negative margins at time of surgery
  - C) Mastectomy
  - D) Complete axillary dissection
3. Which of the following tumor subtypes would NOT be classified as Luminal B ?
  - A) ER+, PR+, Her2+, grade 1
  - B) ER+, PR-, Her2+, grade 3
  - C) ER+, PR+, HER-, grade 3
  - D) ER+, PR+, Her2-, grade 1
4. In the Von Minchwitz 2012 Meta-analysis, which of the following breast cancer subtypes had improved disease free survival after a complete pathologic response to chemotherapy?
  - A) Luminal A
  - B) Luminal B/Her2+
  - C) Luminal B/Her2-
  - D) Non-luminal/Her2+
  - E) Triple negative
  - F) C, D and E
5. Which of the following risk factors made local recurrence most likely in NSABP patients treated with lumpectomy followed by radiation?
  - A) Clinically palpable lymph nodes
  - B) Age < 50
  - C) Residual disease in the breast on surgical pathology
  - D) Residual disease in the lymph nodes on surgical pathology